Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Evan P, Lebois"'
Autor:
Evan P. Lebois, Milissa L. Kaufman, Sherry Winternitz, Lauren A.M. Lebois, Cori A. Palermo, Laura Germine, Luke Scheuer
Publikováno v:
J Psychiatr Res
Background Recovery from dissociative identity disorder (DID) is associated with the process of integration, which includes an increasing sense of self-cohesion and ownership over one's own emotions. Emotion perception is a construction based on inte
Autor:
Claire R. Galloway, Suyashi Singh, Evan P. Lebois, Kaushik Ravipati, Allan I. Levey, Joseph R. Manns, Robert M. Cohen
Publikováno v:
Hippocampus. 28:568-585
Alzheimer’s disease (AD) is a neurodegenerative disease that disproportionately impacts memory and the hippocampus. However, it is unclear how AD pathology influences the activity of surviving neurons in the hippocampus to contribute to the memory
Publikováno v:
ACS Chemical Neuroscience. 7:1393-1405
The muscarinic M1 acetylcholine receptor is a key target for drugs aimed at treating cognitive dysfunction, including the memory impairment in Alzheimer’s disease. The overall question of the current study was to ask how systemic administration of
Publikováno v:
Frontiers in Neural Circuits
Memories are the experiential threads that tie our past to the present. The biological realization of a memory is termed an engram—the enduring biochemical and physiological processes that enable learning and retrieval. The past decade has witnesse
Autor:
Jason P. Schroeder, Thomas J. Esparza, J. Scott Daniels, P. Jeffrey Conn, Evan P. Lebois, David L. Brody, Craig W. Lindsley, Thomas M. Bridges, Allan I. Levey
Alzheimer’s disease (AD) is the leading cause of dementia worldwide, and currently no disease-modifying therapy is available to slow or prevent AD, underscoring the urgent need for neuroprotective therapies. Selective M1 muscarinic acetylcholine re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e09799843a572ceaad0250d6b560d7
https://europepmc.org/articles/PMC5808561/
https://europepmc.org/articles/PMC5808561/
Publikováno v:
Pharmacology. 93:57-64
Acetylcholine signaling through muscarinic receptors has been shown to benefit memory performance in some conditions, but pan-muscarinic activation also frequently leads to peripheral side effects. Drug therapies that selectively target M1 or M4 musc
Publikováno v:
ACS chemical neuroscience. 7(10)
The muscarinic M
Publikováno v:
Neuropharmacology. 136
Muscarinic acetylcholine receptors (mAChRs) are G proteincoupled receptors (GPCRs) that mediate the metabotropic actions of acetylcholine (ACh). There are five subtypes of mAChR, M1 - M5, which are expressed throughout the central nervous system (CNS
Autor:
Gregory J. Digby, Michael R. Wood, P. Jeffrey Conn, Douglas J. Sheffler, Craig W. Lindsley, Evan P. Lebois, Colleen M. Niswender, Atin Lamsal, Christian Sevel, Thomas M. Bridges, Thomas J. Utley
Publikováno v:
ACS Chemical Neuroscience. 3:1025-1036
We previously reported the discovery of VU0364572 and VU0357017 as M(1)-selective agonists that appear to activate M(1) through actions at an allosteric site. Previous studies have revealed that chemical scaffolds for many allosteric modulators conta
Autor:
J. S. Daniels, Heather A. Bimonte-Nelson, Nellie Byun, Ryan D. Morrison, Colleen M. Niswender, A. G. Walker, P.J. Conn, Gregory J. Digby, Carrie K. Jones, M. F. Olive, Hykeyung P. Cho, Sarah E. Mennenga, Craig W. Lindsley, N. E. Nemirovsky, K. Italiano, Michael Bubser, Evan P. Lebois, M. J. Noetzel, Jacob Bode, Bryan W. Camp, Douglas J. Sheffler, Zixiu Xiang, A. A. Davis, T. J. Utley
Publikováno v:
Journal of Neuroscience. 32:8532-8544
M(1) muscarinic acetylcholine receptors (mAChRs) represent a viable target for treatment of multiple disorders of the central nervous system (CNS) including Alzheimer's disease and schizophrenia. The recent discovery of highly selective allosteric ag